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The case for surgery in very early disease
Tsuboi, Tsuboi Kato, Harubumi 
Tokyo Medical University & Hospital, Tokyo, Japan
In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a 
questionnaire to 320 Japanese institutions regarding the prognosis and 
clinicopathological proﬁles of patients who underwent the resection for 
primary lung neoplasms in 1994. We compiled the data for 7408 pa-
tients from 303 institutions (94.7%). Among these, 6644 patients with 
non-small cell histology were studied in terms of prognosis. The 5-year 
survival rate of the entire group was 52.6%. The 5-year survival rates 
by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% 
for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 
35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV 
(n = 147). The difference in prognosis between neighboring stages was 
signiﬁcant except for between IB and IIA and between IIIB and IV. The 
5-year survival rates by pathological (p-) stage were as follows: 79.5% 
for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 
42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 
719) and 20.0% for IV (n = 259). The difference in prognosis between 
neighboring stages was signiﬁcant except for between IB and IIA and 
between IIIB and IV. The survival curves of stages IB and IIA were 
almost superimposed in both c- and p-settings. Otherwise, the present 
TNM staging system seemed to well characterize the stage-speciﬁc 
prognosis in non-small cell lung cancer. The T1 descriptor deﬁnition 
and stage grouping for testing was revised as follows. According to the 
greatest tumor diameter, T1 tumors were divided into T1a tumors (< or 
=2.0 cm) and T1b tumors (2.1-3.0 cm). With these descriptors, new IA 
and IB stages were deﬁned as T1a N0 M0, T1b N0 M0, and T2 N0 M0, 
respectively. For 6644 patients with histologically non-small cell lung 
cancers resected in 1994 and reported in the Japanese Lung Cancer 
Registry Study, the survivals and prognostic difference between neigh-
boring stages were studied. The 5-year survival of the entire population 
was 52.6%. In the clinical setting, the 5-year survivals of the new IA, 
new IB stages were 77.5% and 69.3%, respectively. In the pathologic 
setting, they were 83.7% and 76.0%, respectively. For both clinical and 
pathologic settings, differences between all neighboring stages were 
statistically signiﬁcant. Subcategorization of T1 and minor changes 
in stage grouping results in a system with signiﬁcant differences in 
prognosis between neighboring stages. Additionally, the deﬁnition of 
“non-invasive peripheral early cancer” will be reported by Japanese 
collaboration study in this session
Y1-10 Young Investigators Day, Sat, Sept 1, 08:30 - 16:40
Adjuvant therapies: what we have learned in the last 5 years
Scagliotti, Giorgio V. Selvaggi, Giovanni 
University of Torino, Orbassano, Italy
Following the results of a meta-analysis published 15 years ago, which 
showed a 5-year survival beneﬁt of approximately 5% for adjuvant 
chemotherapy in patients with non-small cell lung cancer (NSCLC) 
[1], various large multicentre studies have investigated the beneﬁt of 
adjuvant chemotherapy in this disease. 
The ﬁndings of the above mentioned meta-analysis failed to impact 
clinical practice, not because the absolute gain was too small but be-
cause such an estimate was still imprecise, ranging from 1% detriment 
to a 10% beneﬁt. In addition, the heterogeneity of surgical procedures 
and the difference in the staging modalities strongly limit the applica-
bility of the results of this meta-analysis. 
Recently published results of ﬁve such studies suggest that adjuvant 
chemotherapy improves survival in patients with stage IIIA and II 
disease, but not in stage I disease [2-6].
These conclusions have been further supported by a recent meta-analy-
sis of individual patient data - the Lung Adjuvant Cisplatin Evaluation 
(LACE) - from ﬁve large studies (ALPI, ANITA, IALT, JBR.10 and 
Big Lung Trial [BLT]) [7]. This analysis involved data from 4,584 
patients with resected NSCLC who were randomized to adjuvant 
chemotherapy chemotherapy or no further systemic therapy. In some of 
these studies, adjuvant radiotherapy was used and left to the discretion 
of each participating centre. Adjuvant chemotherapy was associated 
with a signiﬁcant beneﬁt in overall survival; at 5 years, there was a 
5.3% ± 1.6% absolute increase in survival in favor of adjuvant chemo-
therapy compared with no further systemic therapy. The overall beneﬁt 
observed varied with stage; there was a signiﬁcant beneﬁt for patients 
with stage II and stage III disease whereas there was no signiﬁcant ben-
eﬁt for those with stage IB disease and an apparent detrimental effect 
for those with stage IA disease. 
In contrast to the ﬁndings above, a meta-analysis of several Japanese 
studies of post-operative adjuvant chemotherapy reported a survival 
beneﬁt in patients with stage I disease [8]. Of the 2,003 patients stud-
ied, 95% had stage I disease. Patients were randomized to receive an 
oral adjuvant treatment with tegafur in combination with uracil (UFT) 
for 2 years or no further treatment. The overall survival rates at 5- and 
7-years were signiﬁcantly greater in patients who had received adjuvant 
chemotherapy than in those who had received surgery alone (81.8% vs 
76.5% at 5 years, p = 0.011; 77.2% vs 69.5% at 7 years, p = 0.001).
The concept of relatively mild, low-dose continuous adjuvant therapy 
is attractive, but the absence of conﬁrmatory adjuvant UFT studies 
outside Japan strongly limit the applicability of these data in clinical 
practice because of potential pharmacogenomic differences between 
Japanese and non-Japanese patients.
In two of the positive studies for adjuvant chemotherapy [4,6], a com-
bination of cisplatin and weekly vinorelbine prolonged survival. These 
ﬁndings led to the conclusion that cisplatin/vinorelbine is a regimen 
of choice for adjuvant therapies. However, in another adjuvant trial, 
the combination of cisplatin and vinorelbine did not perform signiﬁ-
cantly better than any other combination tested [2]. Moreover, when 
the combination of cisplatin plus a third-generation agent including 
taxanes, vinorelbine and gemcitabine are compared ‘head to head’ in 
the metastatic or locally advanced settings, no signiﬁcant differences in 
overall survival are observed. 
